



Attorney Docket No.: BHC 031040

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tobias Wunberg, et al.

Group No.: not assigned

Serial No.: 10/579,253

Examiner: not assigned


Filed: 05/11/2006

For: Substituted Dihydroquinazolines II

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 30 May 2007


William F. Gray

**MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450**

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.


**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed within three months of the filing or nationalization of this application, or before the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



William F. Gray
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No. 31018

Telephone: (203) 812-2712

Date: 30 May 2007

Form PTO-1449
(Modified)



U.S. Department of Commerce
Patent and Trademark Office

Serial No.
10/579,253

Group Art Unit
1624

Filing Date
05/11/2006

Atty. Docket No.
BHC 031040

INFORMATION DISCLOSURE CITATION

Applicant(s)
Tobias Wunberg, et al.

U.S. PATENT DOCUMENTS

*		DOCUMENT NO.								DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

NAMES

		DOCUMENT NO.								DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION
		20	04	4	1	7	9	0	05/21/04	WO	Bayer	Healthcare	Ag.	YES
TNT	F1	20	04	4	1	7	9	0	05/21/04	WO	Bayer	Healthcare	Ag.	
TNT	F2	20	04	7	2	0	4	8	08/26/04	WO	Bayer	Healthcare	Ag.	
TNT	F3	19	99	4	1	2	5	3	08/19/99	WO	Tularik	Inc.		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

TNT	R1	Takao Saito, et al., "A Facile and Efficient Carbodiimide-Mediated Synthesis of Dihydroquinazolines via a Tandem Nucleophilic Addition-Intramolecular Hetero Conjugate Addition Annulation Strategy", TETRAHEDRON LETTERS, 1996, vol. 37 no. 2, pp. 209-212 .
TNT	R2	Fengjiang Wang, et al., "Solid-Phase Synthesis of 3,4-Dihydroquinazoline", TETRAHEDRON LETTERS, 1997, vol. 38 no. 50, pp. 8651-8654 .
TNT	R3	Yong Sup Lee, et al., "3,4-Dihydroquinazoline Derivatives as Novel Selective T-type Ca ²⁺ Channel Blockers", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, vol. 14, pp. 3379-3384 .

EXAMINER

\ Tamthom N. Truong\

DATE CONSIDERED 5-27-10

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.